Xilio Therapeutics (XLO) Return on Sales (2024 - 2026)

Xilio Therapeutics has disclosed Return on Sales across 3 years of filings, most recently posting 0.01% for Q1 2026.

• Return on Sales for Q1 2026 came in at 0.01%, up 4.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.01% (up 5.0% YoY), and the FY2025 annual result was 0.01%, up 9.0% from the prior year.
• Return on Sales came in at 0.01% for Q1 2026 at Xilio Therapeutics, down from 0.01% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.0% in Q3 2025 to a low of 0.08% in Q4 2024.
• The 3-year median for Return on Sales is 0.03% (2025), against an average of 0.04%.
• Peak annual rise in Return on Sales reached 7 bps in 2025, while the deepest fall reached 4 bps in 2025.
• Xilio Therapeutics' Return on Sales stood at 0.08% in 2024, then soared by 89 bps to 0.01% in 2025, then fell by 29 bps to 0.01% in 2026.
• The last three Return on Sales figures came in at 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.0% (Q3 2025), per Business Quant data.